Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EPS (Weighted Average and Diluted) (2016 - 2025)

Myriad Genetics (MYGN) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with -$0.07 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 85.11% to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.93 through Dec 2025, down 178.72% year-over-year, with the annual reading at -$3.95 for FY2025, 180.14% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.07 at Myriad Genetics, up from -$0.29 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.3 in Q3 2021, with the low at -$3.57 in Q2 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.51, with a median of -$0.32 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 250.0% in 2021, then plummeted 770.73% in 2025.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.1 in 2021, then tumbled by 420.0% to -$0.52 in 2022, then surged by 34.62% to -$0.34 in 2023, then plummeted by 38.24% to -$0.47 in 2024, then surged by 85.11% to -$0.07 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.07, -$0.29, and -$3.57 for Q4 2025, Q3 2025, and Q2 2025 respectively.